---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-333831"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2021-11-18T23:59:59+00:00"
generated_at: "2026-06-28T07:05:56.375725+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Aligos Therapeutics appoints Bridget Martell, M.D. to Board of Directors

## Summary
- Dr. Martell appointed as Class III director; term expires at 2023 annual meeting.
- She receives $35,000 annual retainer (prorated) and initial option grant of 30,000 shares.
- Board size increased from seven to eight directors.

## SEC filing metadata
- accession: 0001193125-21-333831
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2021-11-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000119312521333831/0001193125-21-333831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000119312521333831/d437129d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-333831
- JSON: https://secwatch.observer/filing/0001193125-21-333831.json
- Plain text: https://secwatch.observer/filing/0001193125-21-333831.txt

## Key facts
- Executive change
  Bridget Martell was appointed as Class III director at Aligos Therapeutics, Inc..
  - Action: appointed
  - Role: Class III director
  source text: appointed Bridget Martell, M.D., to the Board to fill the newly created directorship resulting from the increase in the number of authorized directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799448/000119312521333831/0001193125-21-333831-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.